Matinas BioPharma Announces Pricing of Public Offering of Common Stock

Matinas BioPharma Holdings, Inc. (Matinas BioPharma or the Company) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 27,272,727 shares of its common stock, offered at a price to the public of $1.10 per share for expected gross proceeds of $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.